FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to ...

A recent study found permanent pacemaker infection (PPMI) in 2.09% patients, with infections more prevalent in devices ...

New Guidance Helps Parents Understand Infant Skin Vulnerability and Bacterial Imbalance A child's eczema severity often ...

Experts warn that antibiotic misuse is fueling drug-resistant infections like gonorrhoea and staph, making them harder to ...

Bacteria learned to survive by developing their own defence mechanism against antibiotic use, finds a 2025 study report by ...

To use Pledge's Antibacterial Multisurface Cleaner Spray, you hold the can upright and spray about 8 inches away from any ...

Picking your nose and then sticking those boogers to the wall may be convenient, but could come with unexpected health ...

Antimicrobial resistance and ecological disruption caused by broad-spectrum disinfectants have created an urgent need for precision strategies that remove harmful bacteria without damaging beneficial ...

Researchers have developed a sunlight-activated nanospray that can rapidly kill drug-resistant bacteria, stop bleeding and relieve pain, significantly accelerating the healing of infected diabetic ...

Detailed price information for Armata Pharmaceuticals Inc (ARMP-A) from The Globe and Mail including charting and trades.

Researchers have described how the bacterium Staphylococcus aureus genetically adapts to humans, including mutations that allow some strains to evade the immune system and become resistant to ...

Armata Pharmaceuticals, Inc. ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the ...